Madrigal Pharmaceuticals Inc is a biopharmaceutical company in the clinical stage, primarily focused on creating treatments for non-alcoholic steatohepatitis (NASH), a liver disease. Their main product in development is resmetirom, aimed at treating NASH through a novel approach as a liver-directed thyroid hormone receptor beta agonist. Currently, resmetirom is undergoing Phase 3 clinical trials. The company operates out of West Conshohocken, Pennsylvania.
Wall Street wasted no time Monday, sending the Nasdaq surging past 25,900 while analysts took aim at some of the market's biggest names with fresh upgrades, downgrades, and new coverage that could…
Artificial intelligence has dominated investor attention for two years, but biotech revenue lines are also bending sharply higher. A small group of biotechs is building real commercial businesses around recently approved drugs,…
Insiders continue to scoop up Under Armour and W.R. Berkley shares, and a public offering of International Tower Hill Mines shares prompted huge insider purchases as well.
The past week's most notable insider buying included a biopharmaceutical company, a pipeline company, and an industrial products maker.
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Viking Therapeutics.
John Paulson is among the most well-known billionaires, famous for his long-term investing returns via his hedge fund Paulson & Co. The hedge fund manager has concentrated his portfolio in interesting stocks,…
Chris MacDonald The best investment billionaire John Paulson ever made was a bet against something. He famously predicted the collapse of the U.S. housing market and made a $20 billion profit doing so. Today,…
Warren Buffett's Berkshire Hathaway has bolstered its stake in Occidental Petroleum with a huge purchase of shares. Insider buying is heating up in general.
Some of the biggest insider buying since the Thanksgiving holiday has come from repeat buyers, including Bill Ackman, who continues to build his stake in a real estate firm.
Notable insider buying in the past week included biotech and energy companies, including some that have just gone public. Also, renowned hedge fund manager Bill Ackman continues building a stake in a…
